BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35404148)

  • 1. BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer: A meta-analysis.
    Huang Z; Xiong G
    Int J Biol Markers; 2022 Jun; 37(2):170-177. PubMed ID: 35404148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.
    Yang Y; Xie Y; Xian L
    J Exp Clin Cancer Res; 2013 Mar; 32(1):15. PubMed ID: 23497550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
    Wang LR; He LJ; Wang Y; Li YY; Lou Y; Zhang GB; Li Y; Chen J
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):163-70. PubMed ID: 26003539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
    Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
    J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Bonanno L; Costa C; Majem M; Sanchez JJ; Gimenez-Capitan A; Rodriguez I; Vergnenegre A; Massuti B; Favaretto A; Rugge M; Pallares C; Taron M; Rosell R
    Oncotarget; 2013 Oct; 4(10):1572-81. PubMed ID: 24197907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zhao H; Zhang H; Du Y; Gu X
    Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials.
    Wang L; Liao C; Li M; Zhang S; Yi F; Wei Y; Yu J; Zhang W
    Ann Palliat Med; 2021 Feb; 10(2):1154-1166. PubMed ID: 32954751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.
    Yin JY; Huang Q; Zhao YC; Zhou HH; Liu ZQ
    PLoS One; 2012; 7(6):e38150. PubMed ID: 22761669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
    Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
    BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Kim HT; Lee JE; Shin ES; Yoo YK; Cho JH; Yun MH; Kim YH; Kim SK; Kim HJ; Jang TW; Kwak SM; Kim CS; Ryu JS
    J Clin Oncol; 2008 Dec; 26(36):5972-9. PubMed ID: 19018088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.
    Yang YL; Luo XP; Xian L
    PLoS One; 2014; 9(4):e93997. PubMed ID: 24705847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
    Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
    Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ERCC1, RRM1, TOP1, TOP2A, TYMS, TUBB3, GSTP1 AND BRCA1 mRNA expressions in patients with non-small-cell lung cancer receiving a platinum-based chemotherapy.
    M Tsyganov M; O Rodionov E; M Pevzner A; K Ibragimova M; V Miller S; V Cheremisina O; G Frolova I; A Tuzikov S; V Litviakov N
    J BUON; 2020; 25(4):1728-1736. PubMed ID: 33099907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
    Qin X; Yao W; Li W; Feng X; Huo X; Yang S; Zhao H; Gu X
    Tumour Biol; 2014 May; 35(5):4697-704. PubMed ID: 24443257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.